133 related articles for article (PubMed ID: 28937402)
41. Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?
Stone RM
Best Pract Res Clin Haematol; 2011 Dec; 24(4):509-14. PubMed ID: 22127313
[TBL] [Abstract][Full Text] [Related]
42. Development of minimal residual disease-directed therapy in acute myeloid leukemia.
Freeman SD; Jovanovic JV; Grimwade D
Semin Oncol; 2008 Aug; 35(4):388-400. PubMed ID: 18692689
[TBL] [Abstract][Full Text] [Related]
43. Acute Myeloid Leukemia Immunophenotyping by Flow Cytometric Analysis.
Chen X; Cherian S
Clin Lab Med; 2017 Dec; 37(4):753-769. PubMed ID: 29128067
[TBL] [Abstract][Full Text] [Related]
44. Is a nadir bone marrow required and, if so, what to do with residual disease?
Luger SM
Best Pract Res Clin Haematol; 2011 Dec; 24(4):527-32. PubMed ID: 22127316
[TBL] [Abstract][Full Text] [Related]
45. A comparison of the sensitivity of flow cytometry and bone marrow biopsy in the detection of minimal residual disease in chronic lymphocytic leukemia.
Maloum K; Charlotte F; Divine M; Cazin B; Lesty C; Merle-Béral H;
Haematologica; 2006 Jun; 91(6):860-1. PubMed ID: 16769593
[TBL] [Abstract][Full Text] [Related]
46. Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation.
Hokland P; Ommen HB; Nyvold CG; Roug AS
Br J Haematol; 2012 Sep; 158(5):569-80. PubMed ID: 22738609
[TBL] [Abstract][Full Text] [Related]
47. Is it time to use minimal residual disease to stratify post-remission treatment for acute myeloid leukemia?
Liu H; Stock W
Leuk Lymphoma; 2015; 56(11):3005-7. PubMed ID: 25944470
[No Abstract] [Full Text] [Related]
48. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
[TBL] [Abstract][Full Text] [Related]
49. Issue Highlights-September 2021.
Béné MC
Cytometry B Clin Cytom; 2021 Sep; 100(5):537-540. PubMed ID: 34536066
[No Abstract] [Full Text] [Related]
50. The role of multiparameter flow cytometry for disease monitoring in AML.
Kern W; Bacher U; Haferlach C; Schnittger S; Haferlach T
Best Pract Res Clin Haematol; 2010 Sep; 23(3):379-90. PubMed ID: 21112037
[TBL] [Abstract][Full Text] [Related]
51. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings.
Voskova D; Schoch C; Schnittger S; Hiddemann W; Haferlach T; Kern W
Cytometry B Clin Cytom; 2004 Nov; 62(1):25-38. PubMed ID: 15468339
[TBL] [Abstract][Full Text] [Related]
52. Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study.
Tierens A; Bjørklund E; Siitonen S; Marquart HV; Wulff-Juergensen G; Pelliniemi TT; Forestier E; Hasle H; Jahnukainen K; Lausen B; Jonsson OG; Palle J; Zeller B; Fogelstrand L; Abrahamsson J
Br J Haematol; 2016 Aug; 174(4):600-9. PubMed ID: 27072379
[TBL] [Abstract][Full Text] [Related]
53. Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.
Zhou Y; Othus M; Araki D; Wood BL; Radich JP; Halpern AB; Mielcarek M; Estey EH; Appelbaum FR; Walter RB
Leukemia; 2016 Jul; 30(7):1456-64. PubMed ID: 27012865
[TBL] [Abstract][Full Text] [Related]
54. Monitoring of minimal residual disease in acute myeloid leukemia.
Kern W; Schoch C; Haferlach T; Schnittger S
Crit Rev Oncol Hematol; 2005 Nov; 56(2):283-309. PubMed ID: 16213150
[TBL] [Abstract][Full Text] [Related]
55. Tumor heterogeneity makes AML a "moving target" for detection of residual disease.
Zeijlemaker W; Gratama JW; Schuurhuis GJ
Cytometry B Clin Cytom; 2014 Jan; 86(1):3-14. PubMed ID: 24151248
[TBL] [Abstract][Full Text] [Related]
56. Applications of cytometry to study acute leukemia: in vitro determination of drug sensitivity and detection of minimal residual disease.
Campana D
Cytometry; 1994 Jun; 18(2):68-74. PubMed ID: 7924700
[TBL] [Abstract][Full Text] [Related]
57. Perspective on measurable residual disease testing in acute myeloid leukemia.
Walter RB
Leukemia; 2024 Jan; 38(1):10-13. PubMed ID: 37973819
[No Abstract] [Full Text] [Related]
58. A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma.
de Tute RM; Jack AS; Child JA; Morgan GJ; Owen RG; Rawstron AC
Leukemia; 2007 Sep; 21(9):2046-9. PubMed ID: 17657223
[No Abstract] [Full Text] [Related]
59. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
; Langebrake C; Creutzig U; Dworzak M; Hrusak O; Mejstrikova E; Griesinger F; Zimmermann M; Reinhardt D
J Clin Oncol; 2006 Aug; 24(22):3686-92. PubMed ID: 16877738
[TBL] [Abstract][Full Text] [Related]
60. [Predictable recurrence by regular monitoring minimal residual disease with flow cytometry in the patients with both AML and ALL: a single-center study of 163 cases].
Tong CR; Wang H; Yang JF; Lin YH; Zhang X; Zhao J; Fei XH; Gu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):748-51. PubMed ID: 22339910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
